Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial

Patients with mycosis fungoides (MF) and Sézary syndrome (SS) often require multiple lines of systemic therapy. In the phase 3 MAVORIC study (NCT01728805), mogamulizumab demonstrated superiority to vorinostat in median progression-free survival (PFS) and confirmed overall response rate (ORR) in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Horwitz, Steven, Zinzani, Pier Luigi, Bagot, Martine, Kim, Youn H., Moskowitz, Alison J., Porcu, Pierluigi, Dwyer, Karen, Sun, Wei, Herr, Fiona M., Scarisbrick, Julia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9447791/
https://www.ncbi.nlm.nih.gov/pubmed/34304674
http://dx.doi.org/10.1080/10428194.2021.1953007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9447791/
https://www.ncbi.nlm.nih.gov/pubmed/34304674
http://dx.doi.org/10.1080/10428194.2021.1953007

Ejemplares similares